eligibility_summary
Eligible: 18–75, ECOG 0–1, mCRC progressed after 2nd-line therapy, measurable lesion, liver/lung mets suitable for SBRT, contraception/negative pregnancy test, adequate organ function (ANC≥1.5, Hb≥9, PLT≥80, Cr≤1.5×ULN or CrCl≥60, Alb≥2.8, TBIL≤1.5×, AST/ALT≤2.5×). Exclude: pregnancy/lactation, allergy, GI bleed/obstruction risk, thromboembolism (except PICC), infection, uncontrolled HTN, symptomatic brain mets, comorbidities, immune AEs or prior toxicities ≥G2, recent therapy/trial ≤4 wks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, single-arm trial in previously treated RAS wild-type metastatic colorectal cancer testing SBRT followed by tislelizumab + cetuximab + irinotecan. Interventions and mechanisms: • SBRT (stereotactic body radiotherapy): high-dose focused radiation causing DNA double-strand breaks, tumor debulking, and immunogenic cell death with antigen release, potentially increasing PD-L1 and enhancing response to immunotherapy. • Tislelizumab: anti–PD-1 IgG4 monoclonal antibody, blocks PD-1/PD-L1 signaling to reinvigorate cytotoxic T-cell responses. • Cetuximab: anti-EGFR IgG1 monoclonal antibody, inhibits EGFR-driven RAS–RAF–MAPK and PI3K–AKT signaling in tumor cells and induces ADCC via NK cells. • Irinotecan: cytotoxic topoisomerase I inhibitor (prodrug to SN-38) causing S-phase–specific DNA damage and apoptosis. Targeted cells/pathways: EGFR-expressing RAS WT tumor cells, PD-1–expressing T cells, NK cell–mediated ADCC, tumor DNA replication machinery, TME immune activation post-SBRT.